When was Cleerly founded?

Cleerly was founded in 2016 and raised its 1st funding round 4 years after it was founded.

Where is Cleerly located?

Cleerly is headquartered in Denver, United States. It is registered at 1099 18TH ST STE 2860,DENVER,CO,80202,0.

Who is the current CEO of Cleerly?

James Min of Cleerly. They have also founded 1 company.

How many employees does Cleerly have?

As of Jun 30, 2026, the latest employee count at Cleerly is 359.

Is Cleerly a funded company?

Cleerly is a funded company, having raised a total of $578M across 5 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Apr 03, 2020.

When was the latest funding round of Cleerly?

Cleerly's latest funding was a $***** Series C round on Nov 19, 2024, with participation from 2 investors.

Where does Cleerly rank among its competitors?

Cleerly ranks 2nd amongst 13 active competitors, of which 5 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was HeartFlow, which secured $98.4M in Mar, 2025.

Who are the top competitors of Cleerly?

Cleerly's top competitors include HeartFlow, Lantheus and VentriPoint. Among them, HeartFlow secured the most recent funding round in March, 2025.

Cleerly - 2026 Company Profile, Team, Funding & Competitors

Cleerly is a series C company based in Denver (United States), founded in 2016 by James Min. It operates as a Provider of an AI-driven platform for coronary artery disease assessment. Cleerly has raised $578M in funding from investors like Fidelity Investments, T. Rowe Price and Insight Partners. The company has 13 active competitors, including 5 funded and 3 that have exited. Its top competitors include companies like HeartFlow, Lantheus and VentriPoint.

Company Details

Provider of an AI-driven platform for coronary artery disease assessment. The platform quantifies atherosclerosis by measuring plaque volume, composition, length, and location. It evaluates stenosis severity and determines the likely presence or absence of ischemia. The software aims to reduce the need for additional testing and enhance diagnostic confidence.

Website: cleerlyhealth.com
Social
Email ID: *****@cleerlyhealth.com
Registered Address: 1099 18TH ST STE 2860,DENVER,CO,80202,0

Key Metrics

Founded Year

2016

Location

Denver, United States

Stage

Series C

Total Funding

$578M in 5 rounds

Latest Funding Round

Series C, Nov 19, 2024, $*****

Investors

Fidelity Investments & 21 more

Ranked

2^nd among 13 active competitors

Employee Count

359 as on Jun 30, 2026

Similar Companies

OpenEvidence & 2606 more

View Cleerly's full profile

Cleerly is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Cleerly, Inc. CIN: 32088369080 , United States, Active	Feb 09, 2023	-	-	-

Cleerly has raised a total funding of $578M over 5 rounds. Its first funding round was on Apr 03, 2020. Its latest funding round was a Series C round on Nov 19, 2024 for $*****. 2 investors participated in its latest round. Cleerly has 20 institutional investors and 2 angel investors.

Here is the list of recent funding rounds of Cleerly:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 19, 2024	9383331	Series C	9299636	5148011	2106659	1918452
Aug 30, 2022	2952337	Series C	2654805	7100794	2549598	Piper Sandler & 11 more
Mar 11, 2022	6256727	Series C	6779534	2254591	T. Rowe Price & 1 more	Piper Sandler & 10 more

Access funding benchmarks and valuations. Sign up today!

View details of Cleerly's funding rounds and investors

The founders of Cleerly is James Min. James Min is the CEO of Cleerly.

Here are the details of Cleerly's key team members:

James Min: Founder & CEO of Cleerly.

Cleerly's Board of Directors

Cleerly's board has 16 active members. Lee Cooper, Scott Barclay, Vijay Lathi, Roy Beveridge, Peter Justin Klein, James Earls, James K. Min, Nick Nieslanik, Louis Samson, Word D. Peake III, Oscar Munoz, Kristin Binns, Glenn Steele, Word D. Peake, Jim Hartman and Kevin King are independent board members.

Here is the list of Cleerly's board of directors:

Name	Type	Representing	Status	Duration
Lee Cooper	Independent board member	-	Current	1y 8m
aymtgiq	Independent board member	-	Current	2y 8m
s{gjvzn	Independent board member	-	Current	2y 2m
afqsmtu	Independent board member	-	Current	8y 8m
finjghk	Independent board member	-	Current	2y 1m
wugbkdf	Independent board member	-	Current	2y 3m
zfmhkqh	Independent board member	-	Current	4y 4m
akinmgw	Independent board member	-	Current	3y 6m
jkiyich	Independent board member	-	Current	8y 1m
tpihzyz	Independent board member	-	Current	6y 5m
kzsl{tc	Independent board member	-	Current	2y 3m
lsfxwsv	Independent board member	-	Current	5y 6m
zonxzzn	Independent board member	-	Current	6y 8m
syaxdak	Independent board member	-	Current	6y 1m
dslihro	Independent board member	-	Current	4y 5m
efiebbh	Independent board member	-	Current	5y 8m

View details of Cleerly's Founder profiles and Board Members

Cleerly's employee count trend

Cleerly has 359 employees as of Jun 26. Here is Cleerly's employee count trend over the years:

Uncover Cleerly's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cleerly include HeartFlow, Lantheus and VentriPoint. Here is the list of Top 10 competitors of Cleerly, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	HeartFlow 2007, Redwood City (United States), Public	Provides cardiovascular diagnostic support using analytics	$936M	Bain Capital Life Sciences, Baillie Gifford ... & 23 others	71/100
2nd	Cleerly 2016, Denver (United States), Series C	Provider of an AI-driven platform for coronary artery disease assessment	$578M	T. Rowe Price, Fidelity Investments & 20 others	63/100
3rd	Lantheus 2008, Billerica (United States), Acquired	Developer of diagnostic imaging agents and targeted therapeutics	-	HealthCare Royalty Partners, HHS	56/100
4th	VentriPoint 2005, Toronto (Canada), Public	Heart analysis system	-	-	56/100
5th	Arterys 2012, San Francisco (United States), Series C	Developer of cloud-based AI platform for medical imaging analysis	$70.2M	Temasek, Emergent Medical Partners & 14 others	48/100
6th	Tenoke 2016, Nanjing (China), Seed	Provider of rapid three-dimensional magnetic resonance imaging technology	-	MassChallenge	28/100
7th	Cardio Flow Design 2015, Chiyoda City (Japan), Unfunded	Provider of software solutions for blood flow analysis	-	-	26/100
8th	Peacs 2009, Nieuwerbrug (Netherlands), Unfunded	Provider of diagnostic platform for professionals to detect cardiac abnormalities	-	-	25/100
9th	TandApi 2024, Amsterdam (Netherlands), Unfunded	Provider a cloud-based API platform for screening of ischemic attack	-	-	24/100
10th	Venster Medical 2020, Lenexa (United States), Unfunded	Developer of solutions to support cardiologists and electrophysiologists in improving CRT effectiveness	-	-	24/100